Journal of Gastroenterology

, Volume 54, Issue 12, pp 1061–1069 | Cite as

A novel urinary microRNA biomarker panel for detecting gastric cancer

  • Hiroyasu Iwasaki
  • Takaya ShimuraEmail author
  • Tamaki Yamada
  • Yusuke Okuda
  • Makoto Natsume
  • Mika Kitagawa
  • Shin-ichi Horike
  • Hiromi Kataoka
Original Article—Alimentary Tract



Gastric cancer (GC) is one of the most common causes of cancer deaths worldwide; however, reliable and non-invasive screening methods for GC are not established. Therefore, we conducted this study to develop a biomarker for GC detection, consisting of urinary microRNAs (miRNAs).


We matched 306 participants by age and sex [153 pairs consisting of patients with GC and healthy controls (HCs)], then randomly divided them across three groups: (1) the discovery cohort (4 pairs); (2) the training cohort (95 pairs); and (3) the validation cohort (54 pairs).


There were 22 urinary miRNAs with significantly aberrant expressions between the two groups in the discovery cohort. Upon multivariate analysis of the training cohort, urinary expression levels of miR-6807-5p and miR-6856-5p were significantly independent biomarkers for diagnosis of GC, in addition to Helicobacter pylori (H. pylori) status. A diagnostic panel that combined these 2 miRNAs and H. pylori status distinguished between HC and GC samples with an area under the curve (AUC) = 0.736. In the validation cohort, urinary miR-6807-5p and miR-6856-5p showed significantly higher expression levels in the GC group, and the combination biomarker panel of miR-6807-5p, miR-6856-5p, and H. pylori status also showed excellent performance (AUC = 0.885). In addition, this biomarker panel could distinguish between HC and stage I GC patients with an AUC = 0.748. Urinary expression levels of miR-6807-5p and miR-6856-5p significantly decreased to undetectable level after curative resection of GC.


This novel biomarker panel enables early and non-invasive detection of GC.


Biomarker Gastric cancer Urinary miRNA miR-6807-5p miR-6856-5p 



We thank Yukimi Hashidume-Itoh for handling of urine sample and Takako Onodera for data management of enrolled patients in this study (Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences). We also thank Masahide Ebi at Aichi Medical University, Tomonori Yamada at Nagoya Daini Red Cross Hospital and other clinical colleagues who assisted for the sample collection. This study was supported, in part, by Japan Agency for Medical Research and Development under Grant Number JP19lm0203005j0003 (to T. S.) and the Takeda Science Foundation (to T. S.)

Supplementary material

535_2019_1601_MOESM1_ESM.doc (139 kb)
Supplementary file1 (DOC 139 kb)
535_2019_1601_MOESM2_ESM.pdf (823 kb)
Supplementary file2 (PDF 822 kb)
535_2019_1601_MOESM3_ESM.xlsx (122 kb)
Supplementary file3 (XLSX 121 kb)


  1. 1.
    Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4:1553–688.CrossRefGoogle Scholar
  2. 2.
    Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006;12:4873–4.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017;152:1319–28 e7.CrossRefGoogle Scholar
  4. 4.
    Feng F, Tian Y, Xu G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17:737.CrossRefGoogle Scholar
  5. 5.
    Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest. 2007;117:2059–66.CrossRefGoogle Scholar
  6. 6.
    Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell. 2009;136:26–36.CrossRefGoogle Scholar
  7. 7.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.CrossRefGoogle Scholar
  8. 8.
    Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;108:5003–8.CrossRefGoogle Scholar
  9. 9.
    Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47:784–91.CrossRefGoogle Scholar
  10. 10.
    Liu H, Zhu L, Liu B, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012;316:196–203.CrossRefGoogle Scholar
  11. 11.
    Li C, Li JF, Cai Q, et al. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol. 2013;20(Suppl 3):S397–405.CrossRefGoogle Scholar
  12. 12.
    Zeng Z, Wang J, Zhao L, et al. Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One. 2013;8:e73278.CrossRefGoogle Scholar
  13. 13.
    Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;110:2291–9.CrossRefGoogle Scholar
  14. 14.
    Shin VY, Ng EK, Chan VW, et al. A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Mol Cancer. 2015;14:202.CrossRefGoogle Scholar
  15. 15.
    Zhou X, Zhu W, Li H, et al. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. Sci Rep. 2015;5:11251.CrossRefGoogle Scholar
  16. 16.
    Qiu X, Zhang J, Shi W, et al. Circulating MicroRNA-26a in plasma and its potential diagnostic value in gastric cancer. PLoS One. 2016;11:e0151345.CrossRefGoogle Scholar
  17. 17.
    Azarbarzin S, Feizi MAH, Safaralizadeh R, et al. The value of MiR-383, an intronic MiRNA, as a diagnostic and prognostic biomarker in intestinal-type gastric cancer. Biochem Genet. 2017;55:244–52.CrossRefGoogle Scholar
  18. 18.
    Kao HW, Pan CY, Lai CH, et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget. 2017;8:56389–97.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Hung PS, Chen CY, Chen WT, et al. miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma. PLoS One. 2017;12:e0177346.CrossRefGoogle Scholar
  20. 20.
    McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–72.CrossRefGoogle Scholar
  21. 21.
    Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18:805–35.CrossRefGoogle Scholar
  22. 22.
    Shimura T, Dagher A, Sachdev M, et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila). 2015;8:240–8.CrossRefGoogle Scholar
  23. 23.
    Shimura T, Ebi M, Yamada T, et al. Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget. 2017;8:29247–57.CrossRefGoogle Scholar
  24. 24.
    Shimura T, Iwasaki H, Kitagawa M, et al. Urinary cysteine-rich protein 61 and trefoil factor 3 as diagnostic biomarkers for colorectal cancer. Transl Oncol. 2019;12:539–44.CrossRefGoogle Scholar
  25. 25.
    Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley; 2009.Google Scholar
  26. 26.
    Thery C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Chapter 3:Unit 3 22.Google Scholar
  27. 27.
    Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009;10:R64.CrossRefGoogle Scholar
  28. 28.
    Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733–41.CrossRefGoogle Scholar
  29. 29.
    Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.CrossRefGoogle Scholar
  30. 30.
    Mall C, Rocke DM, Durbin-Johnson B, et al. Stability of miRNA in human urine supports its biomarker potential. Biomark Med. 2013;7:623–31.CrossRefGoogle Scholar
  31. 31.
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefGoogle Scholar
  32. 32.
    Miah S, Dudziec E, Drayton RM, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer. 2012;107:123–8.CrossRefGoogle Scholar
  33. 33.
    Mengual L, Lozano JJ, Ingelmo-Torres M, et al. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer. 2013;133:2631–41.PubMedGoogle Scholar
  34. 34.
    Cardenas-Gonzalez M, Srivastava A, Pavkovic M, et al. Identification, confirmation, and replication of novel urinary MicroRNA biomarkers in lupus nephritis and diabetic nephropathy. Clin Chem. 2017;63:1515–26.CrossRefGoogle Scholar
  35. 35.
    Erbes T, Hirschfeld M, Rucker G, et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer. 2015;15:193.CrossRefGoogle Scholar
  36. 36.
    Debernardi S, Massat NJ, Radon TP, et al. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Am J Cancer Res. 2015;5:3455–66.PubMedPubMedCentralGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology and MetabolismNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Okazaki Public Health Center, OkazakiOkazakiJapan
  3. 3.Advanced Science Research CenterKanazawa UniversityKanazawaJapan

Personalised recommendations